Mid- to large-tier pharmaceutical and financial industry professionals use AI solutions developed by Intelligencia AI to identify undervalued assets and make better investment decisions.
Here are some real-world use cases where we collaborated with our customers to help maximize their return on investment (ROI) and make more informed investment decisions.
Identify High-Performing, Promising Early-Stage Assets and Companies With Confidence
Objective: At Intelligencia AI, we challenged ourselves to create a portfolio of publicly traded, early-stage, pre-proof-of-concept biotech companies with oncology pipelines and a market capitalization between $100M and $1B that outperforms the biotech market benchmark index (XBI-ETF).
Approach: Using our patented methodology, we identified companies based on predicted overperformance against historical benchmarks and selected the top percentile of ranked companies for our portfolio.
Outcome: Between April 2023 and March 2024, we achieved a 60% return and a Sharpe Ratio of 1.83. Similar market-cap companies realized only a 25% return, and XBI-ETF saw a 17% return.
Accelerate Asset Prioritization to Inform Smarter Business Development Decisions in Oncology
Objective: A global pharmaceutical company needed our assistance in prioritizing oncology assets for growth and investment opportunities in the Chinese market.
Approach: Our partner, ZS, leveraged our deep clinical and biological data to conduct a market landscape exercise, assessing market opportunities and unmet needs in the Chinese market. Then, they used our AI-based PTRS assessments to evaluate global assets for their fit with the biopharma customer’s requirements. The assets were prioritized, resulting in a short list, and each asset was assessed on a case-by-case basis.
Outcome: The deliverable produced a highly targeted list of 20 prioritized assets from an original list of more than 1,000 oncology assets for the business development team to focus on. This task, which typically takes months, was completed within eight weeks.
Pinpoint High-Potential Acquisition Targets With Unbiased, AI-Driven PTRS Assessments
Objective: A global biopharma company needed an external PTRS assessment of potential acquisition targets. This was identified as a high-priority need to avoid investment decisions based on overconfident assessments driven by low-quality data and subjective evaluations.
Approach: The biopharma company compared internal assessments of external acquisition targets to those independently generated by Intelligencia AI based on comprehensive, highly curated data and fit-for-purpose AI models.
Outcome: For a potential target, the AI-driven PTRS established by Intelligencia AI was 8%. This placed it in the bottom quartile of assets with the same indication and development stage. However, the internal assessment had placed the PTRS at 45%, a shocking discrepancy of 37%. After using our solution, the company’s internal assessment was reconsidered. The team decided to abandon pursuing the target, which ultimately failed and didn’t receive FDA approval. This decision resulted in significant financial savings.